Status:
TERMINATED
Ultra-High-Resolution Mapping Guided Partial Antral Ablation for AF
Lead Sponsor:
Keimyung University Dongsan Medical Center
Collaborating Sponsors:
Boston Scientific Corporation
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
20-80 years
Brief Summary
The electrical isolation of the pulmonary veins (PVI) is the cornerstone of current ablation techniques for the treatment of atrial fibrillation (AF) because the PV is the most common trigger of AF. W...
Eligibility Criteria
Inclusion
- Age over 20 years old and under 80 years old
- Patients with non-valvular paroxysmal atrial fibrillation
- Patients having atrial fibrillation even after receiving continued treatment with at least 1 antiarrhythmic drug for more than 6 weeks
- Patients who could have informed consent
- Patients who are available for a follow-up of more than at least three months after the catheter ablation
Exclusion
- Patients unsuitable for catheter ablation due to a previous history of pulmonary surgery or structural heart disease
- Patients who cannot receive standard treatments such as anticoagulation therapy needed before the radiofrequency catheter ablation
- Patients in the subject group vulnerable to a clinical study
- Patients who had undergone a prior catheter ablation for atrial fibrillation
Key Trial Info
Start Date :
November 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 7 2021
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT03759912
Start Date
November 20 2018
End Date
August 7 2021
Last Update
May 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keimyung University Dongsan Medical Center
Daegu, South Korea, 41931